Physical Functioning Worse, Depression Elevated, in Some Older Survivors, Study Finds
May 24th 2016Older patients with cancer experience greater declines in physical functioning, according to a recent study published in the journal Cancer. Further, these patients also were at an increased risk of depression.
FDA Approves Nivolumab for Hodgkin Lymphoma
May 17th 2016The FDA granted nivolumab (Opdivo) accelerated approval for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin (Adcetris).
Aromatase Inhibitors, Tamoxifen Similar for Cardiovascular Disease Risk
May 13th 2016A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.
ADT Increases Risk for Depression in Elderly Men With Localized Prostate Cancer
May 4th 2016Although androgen deprivation therapy (ADT) has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether ADT causes clinically significant depression.
Nightly Fasting Found Beneficial to Reduce Breast Cancer Recurrence
May 2nd 2016A study of more than 2400 women with early-stage breast cancer has found that those who fasted 13 hours or more at night reduced their risk of breast cancer recurrence, findings that suggest prolonging the nightly fasting interval may offer a relatively safe nonpharmacologic way for women with early breast cancer to lower their risk of disease recurrence.
Comparing CVD Risk Factors Associated With Adjuvant Endocrine Therapies
May 2nd 2016A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.
Intervention Eases Parental Caregiver Burden During Child's HSCT
April 27th 2016An intervention specifically aimed at reducing the trauma and anxiety that often comes with parenting a child undergoing hematopoietic stem cell transplant proved especially helpful for parents during the time of the actual transplant and subsequent hospitalization.